2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization

Area of Science:

• Medicinal Chemistry
• Structural Biology
• Pharmacology

Background:

• Mitogen-Activated Protein Kinase 2 (MK2) is a key regulator in inflammatory signaling pathways.
• Dysregulation of MK2 is implicated in various inflammatory diseases.
• Targeting MK2 offers a potential therapeutic strategy for inflammatory conditions.

Purpose of the Study:

• To develop novel 2,4-diaminopyrimidine-based inhibitors of MK2.
• To elucidate the binding mode of these inhibitors using structural biology.
• To evaluate the in vitro potency and selectivity of the optimized compounds.

Main Methods:

• Structure-based drug design and optimization of 2,4-diaminopyrimidine derivatives.
• Co-crystallization of inhibitors with MK2 to determine binding interactions.
• In vitro kinase inhibition assays against a panel of kinases.
• Assessment of TNFα production inhibition in human peripheral monocytes.

Main Results:

• A series of novel 2,4-diaminopyrimidine MK2 inhibitors were successfully designed and synthesized.
• Co-crystal structures revealed a unique binding mode for the inhibitors.
• Optimized compounds achieved low nanomolar IC(50) values against MK2.
• Compounds demonstrated moderate selectivity across a kinase panel.
• Selected compounds (15, 31a, 31b) effectively inhibited TNFα production in human monocytes.

Conclusions:

• Structure-based optimization yielded potent and selective 2,4-diaminopyrimidine MK2 inhibitors.
• The identified unique binding mode provides a basis for further drug development.
• These inhibitors represent promising candidates for treating inflammatory diseases driven by MK2 signaling.